Saurabh Zanwar: Clonal plasma cell proportion in the S-phase in multiple myeloma
Saurabh Zanwar, Assistant Professor at Mayo Clinic, shared an article he and his colleagues authored, on X:
“Out now in Blood Cancer Journal!
We present the powerful and independent prognostic impact of the fraction of clonal plasma cells in S-phase (≥ 2%) in the era of R2-ISS and IMS24 risk strata
Top line results and a tread.
MM originate from the post GC plasma cells that typically have a low rate of replication. ≥ 2% CPCs in S-phase, as determined by MFC, noted in 15% and easily integrated into baseline marrow aspirate by flow.
After a median FU of 6 years: Median OS: 3.9 vs 9.2 years – HR of 2 on MVA
– Demonstrates powerful prognostication even in 2+ HRCA, del17p, 1q21+ subgroups
– Can upgrade or downgrade IMS24 risk designation
– Both IMS24 HR and S-phase ≥ 2%: ultra-high-risk: mOS 3.1 years
S-phase fraction:
– identifies a unique cohort of high-risk and functional high-risk patients
– easily integrated into baseline marrow
Median PFS:
1.4 years vs 2.9 years – Independent HR of 1.56 on MVA
both R2-ISS high risk and S-phase identified 53% patients progressing within 18 months, but substantial non-overlap!
Thanks to the amazing mentorship team at MCR!”
Authors: Saurabh Zanwar et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023